StockData
CNBX Pharmaceuticals Inc. logo

CNBX Pharmaceuticals Inc. (CNBX) stock

CNBXOTCPharmaceutical PreparationsFiscal year ends August 31
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jun 24, 2026Score 0/30
$0.00+0.00 (0.00%)

Close on Oct 19, 2026Market cap $197.79KP/E –Yield –

CNBX Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

CNBX Pharmaceuticals's R&D Expenses for the twelve months ending Feb 28, 2026 was $0. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $1.77M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Aug 31, 2025$0-100.0%
FY2024Aug 31, 2024$194.79K-54.9%
FY2023Aug 31, 2023$431.57K-63.5%
FY2022Aug 31, 2022$1.18M-33.2%
FY2021Aug 31, 2021$1.77M+5.3%
FY2020Aug 31, 2020$1.68M+9.0%
FY2019Aug 31, 2019$1.54M+53.8%
FY2018Aug 31, 2018$1.00M+306.5%
FY2017Aug 31, 2017$246.94K+39.0%
FY2016Aug 31, 2016$177.61K+27.4%
FY2015Aug 31, 2015$139.44K–
FY2014Aug 31, 2014$0–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ1 2026Feb 28, 2026$0–
Q1 FY2026CQ4 2025Nov 30, 2025$0–
Q4 FY2025CQ3 2025Aug 31, 2025$0-100.0%
Q3 FY2025CQ2 2025May 31, 2025$0-100.0%
Q2 FY2025CQ1 2025Feb 28, 2025$0-100.0%
Q1 FY2025CQ4 2024Nov 30, 2024$0-100.0%
Q3 FY2024CQ2 2024May 31, 2024$42.88K-83.7%
Q2 FY2024CQ1 2024Feb 29, 2024$107.20K+769.6%
Q1 FY2024CQ4 2023Nov 30, 2023$112.42K+78.8%
Q4 FY2023CQ3 2023Aug 31, 2023$93.24K-43.0%
Q3 FY2023CQ2 2023May 31, 2023$263.12K+5.6%
Q2 FY2023CQ1 2023Feb 28, 2023$12.33K-96.3%
Q1 FY2023CQ4 2022Nov 30, 2022$62.89K-85.7%
Q4 FY2022CQ3 2022Aug 31, 2022$163.60K-65.3%
Q3 FY2022CQ2 2022May 31, 2022$249.06K-54.8%
Q2 FY2022CQ1 2022Feb 28, 2022$330.58K+4.6%
Q1 FY2022CQ4 2021Nov 30, 2021$440.04K+1.5%
Q4 FY2021CQ3 2021Aug 31, 2021$471.00K+17.2%
Q3 FY2021CQ2 2021May 31, 2021$550.84K+48.8%
Q2 FY2021CQ1 2021Feb 28, 2021$315.96K-28.9%
Q1 FY2021CQ4 2020Nov 30, 2020$433.73K-6.9%
Q4 FY2020CQ3 2020Aug 31, 2020$401.93K-15.9%
Q3 FY2020CQ2 2020May 31, 2020$370.08K+10.9%
Q2 FY2020CQ1 2020Feb 29, 2020$444.42K+3.8%
Q1 FY2020CQ4 2019Nov 30, 2019$466.03K+53.2%
Q4 FY2019CQ3 2019Aug 31, 2019$477.77K+13.0%
Q3 FY2019CQ2 2019May 31, 2019$333.76K+26.7%
Q2 FY2019CQ1 2019Feb 28, 2019$428.04K+306.7%
Q1 FY2019CQ4 2018Nov 30, 2018$304.18K+43.3%
Q4 FY2018CQ3 2018Aug 31, 2018$422.85K+284.0%
Q3 FY2018CQ2 2018May 31, 2018$263.51K+286.5%
Q2 FY2018CQ1 2018Feb 28, 2018$105.24K+126.2%
Q1 FY2018CQ4 2017Nov 30, 2017$212.31K+859.2%
Q4 FY2017CQ3 2017Aug 31, 2017$110.11K+100.0%
Q3 FY2017CQ2 2017May 31, 2017$68.17K–
Q2 FY2017CQ1 2017Feb 28, 2017$46.53K–
Q1 FY2017CQ4 2016Nov 30, 2016$22.13K–
Q4 FY2016CQ3 2016Aug 31, 2016$55.05K–

More CNBX Pharmaceuticals figures

See a number that looks wrong?